DAPIVIRINE, 25mg, vaginal ring


Valid Article - Non-nucleoside reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list


Add Kit To Wishlist


DAPIVIRINE vaginal ring

Full Name

Dapivirine Vaginal Ring (DPV-VR)

Therapeutic Action

Antiretrovial, non-nucleoside reverse transcriptase inhibitor (NNRTI).

By blocking reverse transcriptase, dapivirine, which is released from the silicone ring at the site of potential infection in the vagina, stops the virus from multiplying and spreading in the body if the woman is exposed to the virus.


Pre-exposure prophylaxis (PrEP) of HIV-1 infection through vaginal intercourse in HIV-uninfected women aged 18 years and older in combination with safer sex practices when oral PrEP is not/cannot be used or is not available.

To be offered alongside other additional HIV prevention options, STIs diagnosis and treatment and contraception options.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Vaginal delivery system.

Soft silicone vaginal ring with an outer diameter of 56 mm and a section diameter of 7.7 mm. Easy to bend and insert.

Each ring contains 25 mg of davirapine and releases approximatively 4 mg of daviprine over a period of one month.

The vaginal ring is inserted into the vagina and releases dapivirine slowly over a period of one month. The ring should be removed after four weeks of use and replaced immediately with a new ring.

For instructions for use, see below.


Precautions for Use

Contraindicated in women with unknown or positive HIV status

Pregnancy and breastfeeding: there is limited data regarding the use of dapivirine ring in pregnant and breastfeeding women.


  • Below 25°C - Protect from sunlight
  • Keep in the original packaging.